Literature DB >> 9386050

Stage I ovarian carcinoma: specialty-related differences in survival and management.

L E Puls1, R Carrasco, M S Morrow, D Blackhurst.   

Abstract

BACKGROUND: In patients with FIGO (International Federation of Gynecology and Obstetrics) stage I ovarian carcinoma given care with or without subspecialists, we compared completeness of initial staging and disease-free survival.
METHODS: Two groups of patients with stage I ovarian carcinoma were compared. Patients were managed by either gynecologic oncologists or community-based physicians. The two groups were compared for similarities in demographic, tumor, and substage characteristics and survival differences.
RESULTS: Fifty-four patients with stage I ovarian cancer were included. The two groups were comparable in age, gravidity, parity, grade, and substage. Substaging was determined to be adequate in 100% of the gynecologic oncologist group and 28% of the community-based group. Postoperative chemotherapy was given to 79% and 36% of the two groups, respectively. Six-year survival was 90% in the gynecologic oncologist group and 68% in the community-based group.
CONCLUSIONS: Of these two groups of patients with stage I ovarian cancer, the group managed without gynecologic oncology involvement had significantly less adequate staging, decreased administration of chemotherapy, and lower survival rates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386050     DOI: 10.1097/00007611-199711000-00008

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  Surgical outcomes in women with ovarian cancer.

Authors:  Laurie M Elit; Susan J Bondy; Lawrence P Paszat; Eric J Holowaty; Gillian M Thomas; Therese A Stukel; Mark N Levine
Journal:  Can J Surg       Date:  2008-10       Impact factor: 2.089

2.  Will patients benefit from regionalization of gynecologic cancer care?

Authors:  Kathleen F Brookfield; Michael C Cheung; Relin Yang; Margaret M Byrne; Leonidas G Koniaris
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.